Clinical Trial Update: A Study of ABT-414 in Subjects With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of ABT-414 (depatuxizumab mafodotin) in subjects with solid tumors, focusing on squamous cell carcinomas; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma

Drugs mentioned

• ABT-414 (depatuxizumab mafodotin)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Squamous Cell Tumors | Phase 1 | Status: COMPLETED